potassium phosphate, dibasic 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4206 7758-11-4

Description:

MoleculeDescription

Synonyms:

  • potassium phosphate, dibasic
  • dibasic potassium phosphate
  • dipotassium hydrogen orthophosphate
  • dipotassium hydrogen phosphate
  • Molecular weight: 174.17
  • Formula: HK2O4P
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 83.42
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 1975 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sleep disorder 138.61 18.58 107 5461 197923 90424956
Product use issue 80.45 18.58 100 5468 329819 90293060
Infection 79.24 18.58 104 5464 361990 90260889
Myocardial reperfusion injury 67.40 18.58 11 5557 133 90622746
Treatment failure 58.37 18.58 82 5486 303846 90319033
Rash 47.59 18.58 131 5437 795969 89826910
Brain death 42.79 18.58 14 5554 4007 90618872
Cytokine release syndrome 38.42 18.58 23 5545 27950 90594929
Torsade de pointes 33.30 18.58 17 5551 15165 90607714
Apallic syndrome 32.83 18.58 8 5560 788 90622091
Hypoxic-ischaemic encephalopathy 29.41 18.58 11 5557 4657 90618222
Blood phosphorus decreased 28.61 18.58 11 5557 5023 90617856
Malignant neoplasm progression 23.74 18.58 31 5537 106839 90516040
Hypophosphataemia 22.46 18.58 13 5555 14841 90608038
Mucosal dryness 21.93 18.58 8 5560 3159 90619720
Encephalopathy 21.82 18.58 20 5548 46424 90576455
Electrocardiogram QT prolonged 20.92 18.58 24 5544 72432 90550447
Nephrocalcinosis 20.32 18.58 6 5562 1226 90621653
Skin lesion 19.35 18.58 17 5551 37348 90585531

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxic epidermal necrolysis 70.16 19.38 34 2641 26716 42591944
Cytokine release syndrome 46.54 19.38 31 2644 44496 42574164
Testicular haemorrhage 23.70 19.38 5 2670 252 42618408

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 85.07 16.35 53 6645 70253 110512348
Myocardial reperfusion injury 67.48 16.35 11 6687 134 110582467
Toxic epidermal necrolysis 54.46 16.35 37 6661 56690 110525911
Brain death 36.25 16.35 14 6684 6559 110576042
Blood phosphorus decreased 30.80 16.35 13 6685 7652 110574949
Apallic syndrome 30.33 16.35 8 6690 1098 110581503
Encephalopathy 29.26 16.35 30 6668 81025 110501576
Therapeutic reaction time decreased 28.25 16.35 11 6687 5268 110577333
Torsade de pointes 27.22 16.35 17 6681 22583 110560018
Testicular haemorrhage 23.96 16.35 5 6693 248 110582353
Hypoxic-ischaemic encephalopathy 22.78 16.35 11 6687 8836 110573765
Nephrocalcinosis 22.19 16.35 7 6691 1807 110580794
Hypokalaemia 21.29 16.35 39 6659 182409 110400192
Mucosal dryness 19.73 16.35 8 6690 4255 110578346
Hypophosphataemia 19.22 16.35 16 6682 33166 110549435
Neurotoxicity 17.78 16.35 17 6681 42190 110540411
Penile haemorrhage 17.61 16.35 5 6693 903 110581698
Immune effector cell-associated neurotoxicity syndrome 17.50 16.35 11 6687 14771 110567830
Diarrhoea 17.31 16.35 123 6575 1139382 109443219
Groin infection 16.80 16.35 5 6693 1065 110581536

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:35225 buffer
CHEBI has role CHEBI:231911 renoprotective agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypophosphatemia off-label use 4996001
Calcium renal calculus off-label use 427649000
Anuria contraindication 2472002 DOID:2983
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Hyperphosphatemia contraindication 20165001 DOID:0050459
Sarcoidosis contraindication 31541009 DOID:11335
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Hypercalcemia contraindication 66931009 DOID:12678
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Oliguria contraindication 83128009
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Hyporeninemic hypoaldosteronism contraindication 236464008
Azotemia contraindication 445009001
Severe dehydration contraindication 450316000




🐶 Veterinary Drug Use

SpeciesUseRelation
Cattle Dehydration associated with diarrhea Indication
Cattle Early treatment of scouring Indication
Cattle Treatment following intravenous fluid therapy Indication

🐶 Veterinary products

ProductApplicantIngredients
Re-Sorb, Vytrate Zoetis Inc. 6

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) POTASSIUM PHOSPHATES CMP DEV LLC N212121 Sept. 19, 2019 DISCN SOLUTION INTRAVENOUS 10632150 April 19, 2039 POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11813291 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/100ML (11.8MG/ML);1.12GM/100ML (11.2MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11925661 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11813291 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER
1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE FRESENIUS KABI USA N212832 May 9, 2025 RX SOLUTION INTRAVENOUS 11925661 Oct. 12, 2041 METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4018694 VUID
N0000147003 NUI
D02403 KEGG_DRUG
4018694 VANDF
C0138037 UMLSCUI
CHEBI:131527 CHEBI
CHEMBL1200459 ChEMBL_ID
DB09414 DRUGBANK_ID
24450 PUBCHEM_CID
55018 RXNORM
NOCODE MMSL
007401 NDDF
010466 NDDF
CI71S98N1Z UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.03 g INTRAVENOUS NDA 23 sections
Isolyte P in Dextrose HUMAN PRESCRIPTION DRUG LABEL 5 0264-7730 INJECTION, SOLUTION 0.03 g INTRAVENOUS NDA 23 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0202 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0202 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0206 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0206 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0210 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0210 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0214 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 20 0338-0214 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1113 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1115 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1115 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1123 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1123 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1125 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1125 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1142 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1142 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1144 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1144 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1145 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1145 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1147 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1147 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1148 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-1148 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-7020 INJECTION 261 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-7020 INJECTION 261 mg INTRAVENOUS NDA 20 sections